AnaptysBio (ANAB) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for AnaptysBio (NASDAQ: ANAB):

• 5/16/2026 – AnaptysBio was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 5/15/2026 – AnaptysBio was given a new $90.00 price target by Leerink Partners.
• 5/13/2026 – AnaptysBio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/13/2026 – AnaptysBio had its price target raised by UBS Group AG from $60.00 to $76.00. They now have a “buy” rating on the stock.
• 5/13/2026 – AnaptysBio had its price target raised by Barclays PLC from $63.00 to $75.00. They now have an “overweight” rating on the stock.
• 5/4/2026 – AnaptysBio was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/4/2026 – AnaptysBio had its price target lowered by Piper Sandler from $95.00 to $93.00. They now have an “overweight” rating on the stock.
• 4/28/2026 – AnaptysBio had its price target raised by Leerink Partners from $66.00 to $85.00. They now have an “outperform” rating on the stock.
• 4/25/2026 – AnaptysBio was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/22/2026 – AnaptysBio had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – AnaptysBio had its price target lowered by UBS Group AG from $90.00 to $60.00. They now have a “buy” rating on the stock.
• 3/31/2026 – AnaptysBio had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an “overweight” rating on the stock.
• 3/30/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.

Insider Activity

In related news, CEO Daniel Faga sold 17,679 shares of the firm’s stock in a transaction dated Friday, March 27th. The stock was sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the sale, the chief executive officer directly owned 495,965 shares in the company, valued at approximately $30,556,403.65. This trade represents a 3.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John P. Schmid sold 20,645 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $56.11, for a total value of $1,158,390.95. Following the sale, the director owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. This trade represents a 39.50% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.